Sung Tae-Jung
Department of Pediatrics, School of Medicine, Hallym University, Seoul, Korea.
Korean J Pediatr. 2010 Dec;53(12):989-93. doi: 10.3345/kjp.2010.53.12.989. Epub 2010 Dec 31.
Although numerous clinical observational studies have been conducted over a period of over 30 years, the clinical significance of Ureaplasma infection is still under debate. The Ureaplasma speices. is a commensal in the female genital tract and considered to have of low virulence; however, Ureaplasma colonization has been associated with infertility, stillbirth, preterm delivery, histologic chorioamnionitis, and neonatal morbidities, including congenital pneumonia, meningitis, bronchopulmonary dysplasia, and perinatal death. Recently, Ureaplasma was subdivided into 2 separate species and 14 serovars. Ureaplasma parvum is known as biovar 1 and contains serovars 1, 3, 6, and 14, and Ureaplasma urealyticum (biovar 2) contains the remaining serovars (2, 4, 5, and 7-13). The existence of differences in pathogenicities of these 14 serovars and 2 biovars is controversial. Although macrolides are the only antimicrobial agents currently available for use in neonatal ureaplasmal infections, in the current clinical field, it is difficult to make decisions regarding which antibiotics should be used. Future investigations involving large, multicenter, randomized, controlled studies are needed before proper recommendations can be made for clinical practice.
尽管在过去30多年里已经进行了大量临床观察研究,但解脲脲原体感染的临床意义仍存在争议。解脲脲原体属是女性生殖道的共生菌,被认为毒力较低;然而,解脲脲原体定植与不孕、死产、早产、组织学绒毛膜羊膜炎以及新生儿疾病有关,包括先天性肺炎、脑膜炎、支气管肺发育不良和围产期死亡。最近解脲脲原体被细分为2个独立的种和14个血清型。微小脲原体被称为生物变种1,包含血清型1、3、6和14,而解脲脲原体(生物变种2)包含其余血清型(2、,4、5和7 - 13)。这14个血清型和2个生物变种在致病性上是否存在差异仍存在争议。尽管大环内酯类药物是目前唯一可用于新生儿解脲脲原体感染的抗菌药物,但在当前临床领域,很难决定应使用哪种抗生素。在能够为临床实践提出适当建议之前,需要开展涉及大规模、多中心、随机对照研究的进一步调查。